6 December 2022 - Acting chief medical officer Michael Kidd has contradicted the nation’s top advisers on Covid-19 treatments on the efficacy of Australia’s most widely prescribed antiviral medication, molnupiravir, insisting it is highly effective for older Australians.

The National Clinical Evidence Taskforce on Friday issued new guidance on molnupiravir having determined, based on a large UK clinical trial, that there was “high certainty evidence that molnupiravir does not have an impact on the combined endpoint of hospitalisation and/or mortality in multiply-vaccinated adults with mild Covid-19 and one or more risk factors for disease progression”.

Read The Australian article